Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$692K Buy
14,365
+6,688
+87% +$312K 0.15% 118
2025
Q4
$372K Sell
7,677
-496
-6% -$24.6K 0.09% 248
2025
Q3
$386K Buy
+8,173
New +$394K 0.16% 124
2025
Q2
Sell
-4,448
Closed -$247K 321
2025
Q1
$247K Sell
4,448
-6,542
-60% -$354K 0.15% 131
2024
Q4
$530K Buy
10,990
+194
+2% +$9.86K 0.34% 42
2024
Q3
$622K Buy
10,796
+534
+5% +$28.8K 0.41% 36
2024
Q2
$498K Sell
10,262
-319
-3% -$15.4K 0.35% 45
2024
Q1
$514K Sell
10,581
-351
-3% -$17.1K 0.38% 40
2023
Q4
$544K Buy
+10,932
New +$535K 0.46% 33

Other funds holding SNY

Abel Hall LLC's SNY Position: Q1 2026 in Review

Abel Hall LLC increased its Sanofi (SNY) stake by 87% in Q1 2026, buying an estimated $312K and bringing the position to 14,365 shares worth $692K. The position accounts for 0.15% of the portfolio, ranked #118.

Abel Hall LLC first reported a position in SNY in Q4 2023 and has held it in 9 quarters since. 737 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

  • Abel Hall LLC held 14,365 shares of Sanofi worth $692K as of Q1 2026.
  • Abel Hall LLC bought 6,688 Sanofi shares in Q1 2026, an estimated $312K.
  • Sanofi made up 0.15% of Abel Hall LLC's portfolio in Q1 2026, its #118 holding.
  • Abel Hall LLC first reported a position in Sanofi in Q4 2023 and has held it in 9 quarters since.
  • 737 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.